We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

54 hedge funds and large institutions have $288M invested in Akero Therapeutics in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

41% more capital invested

Capital invested by funds: $205M → $288M (+$83.7M)

13% more funds holding

Funds holding: 48 → 54 (+6)

5.15% more ownership

Funds ownership: 39.46% → 44.62% (+5.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+6
Holders Change %
+12.5%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
13
Reduced
8
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$29.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.97M
3
HA
HHLR Advisors
Cayman Islands
+$7.55M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$6.56M
5
BlackRock
BlackRock
New York
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.11M
2
FCM
Farallon Capital Management
California
-$2.87M
3
Millennium Management
Millennium Management
New York
-$2.19M
4
MIM
Monashee Investment Management
Massachusetts
-$2.11M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$9K +$9.31K +400 New
TAM
52
Tyers Asset Management
Texas
$8K – – –
Citigroup
53
Citigroup
New York
$5K +$4.91K +211 New
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$1K +$1.02K +44 New
FCM
55
Farallon Capital Management
California
– -$2.87M -150,000 Closed
MIM
56
Monashee Investment Management
Massachusetts
– -$2.11M -110,000 Closed
Alyeska Investment Group
57
Alyeska Investment Group
Illinois
– -$1.24M -64,688 Closed
MWNA
58
Marshall Wace North America
New York
– -$1.04M -54,304 Closed
DIM
59
DC Investments Management
Virginia
– -$627K -32,752 Closed
LCM
60
Landscape Capital Management
New Jersey
– -$485K -25,352 Closed
ZP
61
Zimmer Partners
New York
– -$479K -25,000 Closed
LCM
62
Laurion Capital Management
New York
– -$431K -22,500 Closed
BCM
63
BlueCrest Capital Management
Jersey
– -$326K -17,000 Closed
DKCM
64
Davidson Kempner Capital Management
New York
– -$294K -15,000 Closed
Norges Bank
65
Norges Bank
Norway
– -$287K -15,000 Closed
MCM
66
Moore Capital Management
New York
– -$192K -10,000 Closed
SG Americas Securities
67
SG Americas Securities
New York
– -$192K -10,000 Closed
PHK
68
Point72 Hong Kong
Hong Kong
– -$77K -4,008 Closed
TRCT
69
Tower Research Capital (TRC)
New York
– -$26K -1,381 Closed
GAM
70
Griffin Asset Management
New York
– -$25K -1,300 Closed
CCA
71
Catalyst Capital Advisors
New York
– -$8K -416 Closed
1 2
3

AKRO Hedge Fund Activity: Q3 2019 in Review

54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2019, worth a combined $288M — up 41% from $205M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AKRO positions and 17 closed out — a net gain of 7 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $29.5M. The largest seller was BVF Inc, cutting an estimated $4.11M.

  • 54 institutional investors held Akero Therapeutics (AKRO) as of Q3 2019, up from 48 in Q2 2019.
  • Funds reported $288M of Akero Therapeutics stock for Q3 2019, up 41% quarter-over-quarter.
  • 24 funds opened new Akero Therapeutics positions in Q3 2019 and 17 closed out, a net change of +7 holders.
  • The largest Akero Therapeutics buyer in Q3 2019 was Janus Henderson Group, an estimated $29.5M added.
  • The largest Akero Therapeutics seller in Q3 2019 was BVF Inc, an estimated $4.11M sold.

Based on aggregated 13F filings for Q3 2019.